// App-Quantinova.ai

528 : TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).

Researchers

Presenter

  • Rachel A. Freedman

Principal Investigators

  • Rebecca Sue Gelman

  • Jeffrey Scott Wefel

  • Shannon Puhalla

  • Nicole Ryabin

  • Elizabeth S Lawler

  • Nuhad K. Ibrahim

  • Minetta C. Liu

  • Antonio C. Wolff

  • Eric P. Winer

  • Nancy U. Lin

  • Alarice Lowe

  • Nathalie Agar

  • Kimberly L. Blackwell

  • Roisin M. Connolly

  • Polly Ann Niravath

  • Catherine H. Van Poznak

Medical Centers

  • The Johns Hopkins Hospital and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

  • Dana-Farber Cancer Institute, Boston, MA

  • Brigham and Womens Hospital, Boston, MAThe University of Texas MD Anderson Cancer Center, Houston, TXDuke Cancer Institute, Durham, NC

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Mayo Clinic, Rochester, MN

  • Baylor College of Medicine, Houston, TX

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of Pittsburgh Medical Center, Womens Cancer Program at Magee-Womens Hospital of UPMC, Pittsburgh, PA

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • Neratinib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01494662

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved